Inhaled colistin
Phase 3Small molecule
Inhaled colistin is one of 48 small molecule programs targeting Bronchitis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Xolair
RochePreclinical
Cinqair
TevaPreclinical
Inhaled colistin
MMahidol University
Phase 3
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Spiriva
Boehringer IngelheimPreclinical
Atrovent
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Symbicort
AstraZenecaPreclinical
Aciphex
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhaled colistin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMahidol University